Liminatus Pharma, Inc.
LIMNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $90.1K in total; no superinvestor holds it.
Other share classesLIMN
13F holders, Q1 2026
Institutional positions in Liminatus Pharma, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −4 vs. Q4 2025
- Shares held
- 1.59M
- −873.3K (−35.5%) vs. Q4 2025
- Total value
- $72.6K
- −$22.4K (−23.6%) vs. Q4 2025
- New holders
- 0
- 1 more added
- Sold out
- 4
- 3 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LIMNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $90.1K |
| Q1 2026 | 21 | $72.6K |
| Q4 2025 | 25 | $95.0K |
| Q3 2025 | 27 | $400.3K |
| Q2 2025 | 26 | $837.0K |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Liminatus Pharma, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Aristeia Capital LLC | 319,510 | $15.7K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 268,199 | $13.1K | 0.00% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 233,761 | $11.5K | 0.00% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 122,688 | $6.01K | 0.00% | 00.0% | Unchanged |
| Moore Capital Management, LP | 125,000 | $5.00K | 0.00% | 00.0% | Unchanged |
| MMCAP International Inc. SPC | 111,745 | $4.47K | 0.00% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 83,353 | $3.33K | 0.00% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 50,000 | $2.00K | 0.00% | 00.0% | Unchanged |
| Periscope Capital Inc. | 47,500 | $1.90K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 39,373 | $1.57K | 0.00% | −23,422−37.3% | Reduced |
| Toronto Dominion Bank | 35,100 | $1.40K | 0.00% | 00.0% | Unchanged |
| LMR Partners LLP | 29,961 | $1.20K | 0.00% | 00.0% | Unchanged |
| Arena Capital Advisors, LLC- CA | 29,166 | $1.17K | 0.00% | 00.0% | Unchanged |
| Flow Traders U.S. LLC | 13,110 | $1.00K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 24,274 | $971 | 0.00% | 00.0% | Unchanged |
| Limestone Investment Advisors LP | 22,562 | $902 | 0.00% | 00.0% | Unchanged |
| GTS Securities LLC | 21,029 | $841 | 0.00% | −8,671−29.2% | Reduced |
| DuPont Capital Management Corp | 6,250 | $306 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,507 | $180 | 0.00% | +295+7.0% | Added |
| HGC Investment Management Inc. | 1,250 | $50 | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 100 | $4 | 0.00% | −805,077−100.0% | Reduced |
| Highbridge Capital Management LLC | 0 | $0 | 0.00% | – | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −23,906−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −12,400−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −100−100.0% | Sold out |